Cargando…

Immune Checkpoint Inhibitors: Changing the Treatment Landscape in Esophagogastric Adenocarcinoma

In the West, recent decades have demonstrated an epidemiological trend towards esophago-gastric adenocarcinomas (EGAC), with considerable associated mortality. Historically, chemotherapy has represented the sole systemic treatment option in the advanced EGAC setting, in addition to complementing the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lynch, Emer, Duffy, Austin G., Kelly, Ronan J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865965/ https://www.ncbi.nlm.nih.gov/pubmed/36678598 http://dx.doi.org/10.3390/ph16010102

Ejemplares similares

Role of Immunotherapy in Gastroesophageal Cancers—Advances, Challenges and Future Strategies
por: Lynch, Emer, et al.
Publicado: (2023)

LAG-3 Inhibitors: Novel Immune Checkpoint Inhibitors Changing the Landscape of Immunotherapy
por: Ibrahim, Rebecca, et al.
Publicado: (2023)

Current surgical treatment of esophagogastric junction adenocarcinoma
por: Zhang, Shun, et al.
Publicado: (2019)

Role of PD-1 Inhibitors in the Treatment of Esophagogastric Adenocarcinoma: Patient Selection and Reported Outcomes
por: Epistola, Raisa, et al.
Publicado: (2023)

Surgical principles for optimal treatment of esophagogastric junction adenocarcinoma
por: Nobel, Tamar, et al.
Publicado: (2019)

Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
por: Ruff, Samantha M., et al.
Publicado: (2023)

Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
por: Machairas, Nikolaos, et al.
Publicado: (2022)

Rapidly Evolving Treatment Landscape for Metastatic Esophagogastric Carcinoma: Review of Recent Data
por: Kankeu Fonkoua, Lionel Aurelien, et al.
Publicado: (2021)

Current treatments and outlook in adenocarcinoma of the esophagogastric junction: a narrative review
por: Cao, Fei, et al.
Publicado: (2022)

The Immune Checkpoint Landscape in Tumor Cells of Pancreatic Ductal Adenocarcinoma
por: Loch, Florian N., et al.
Publicado: (2023)

The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors
por: Alimonti, Paolo, et al.
Publicado: (2023)

Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors
por: Zhu, Yingming, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology
por: Choucair, Khalil, et al.
Publicado: (2022)

The correlation between the margin of resection and prognosis in esophagogastric junction adenocarcinoma
por: Pang, Tao, et al.
Publicado: (2023)

The landscape of immune checkpoint inhibitor therapy in advanced lung cancer
por: Wang, Chengdi, et al.
Publicado: (2021)

Integrative proteomic characterization of adenocarcinoma of esophagogastric junction
por: Li, Shengli, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer
por: Lopez-Beltran, Antonio, et al.
Publicado: (2021)

Application of Immune Checkpoint Inhibitors in the Treatment of Cholangiocarcinoma
por: Zeng, Fan-li, et al.
Publicado: (2021)

Revising the Landscape of Cytokine-Induced Killer Cell Therapy in Lung Cancer: Focus on Immune Checkpoint Inhibitors
por: Vaseq, Rohulla, et al.
Publicado: (2023)

The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition
por: Varricchi, Gilda, et al.
Publicado: (2019)

Current Landscape and Potential Challenges of Immune Checkpoint Inhibitors in Microsatellite Stable Metastatic Colorectal Carcinoma
por: San-Román-Gil, María, et al.
Publicado: (2023)

The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers
por: Zhu, Lingling, et al.
Publicado: (2021)

Changes of Quality of Life after Gastric Tube Reconstruction in Adenocarcinoma of the Esophagogastric Junction
por: Shen, Chaoyong, et al.
Publicado: (2013)

Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights
por: Balsano, Rita, et al.
Publicado: (2023)

The tumor microenvironment of pancreatic adenocarcinoma and immune checkpoint inhibitor resistance: a perplex relationship
por: Sahin, Irem, et al.
Publicado: (2020)

Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors
por: Bertucci, François, et al.
Publicado: (2021)

Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
por: Wang, Wen-Ping, et al.
Publicado: (2012)

Considerations for treatment duration in responders to immune checkpoint inhibitors
por: Marron, Thomas U, et al.
Publicado: (2021)

The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation
por: Humphries, Matthew P., et al.
Publicado: (2020)

Landscape of immune checkpoint inhibitor-related adverse events in Chinese population
por: Li, Li, et al.
Publicado: (2020)

Review of the Immune Checkpoint Inhibitors in the Context of Cancer Treatment
por: Alturki, Norah A.
Publicado: (2023)

Immune checkpoint inhibitors in the treatment of virus-associated cancers
por: Gao, Peipei, et al.
Publicado: (2019)

Overview of Immune Checkpoint Inhibitors in Gynecological Cancer Treatment
por: Pirš, Boštjan, et al.
Publicado: (2022)

The Association Between Immune Characteristic and Clinical Pathology in Chinese Patients with Adenocarcinoma of Esophagogastric Junction
por: Wang, Yangyang, et al.
Publicado: (2020)

Myeloid-Derived Suppressor Cells in Immune Microenvironment Promote Progression of Esophagogastric Junction Adenocarcinoma
por: Wang, Ying, et al.
Publicado: (2021)

Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma
por: Akhuba, Liia, et al.
Publicado: (2023)

Cardiotoxicity of immune checkpoint inhibitors
por: Varricchi, Gilda, et al.
Publicado: (2017)

Nomogram predicted survival of patients with adenocarcinoma of esophagogastric junction
por: Zhou, Zhangjian, et al.
Publicado: (2015)

Role of Nampt and Visceral Adiposity in Esophagogastric Junction Adenocarcinoma
por: Li, Haijun, et al.
Publicado: (2017)

Esophagogastric junction adenocarcinoma: Preoperative chemoradiation or perioperative chemotherapy?
por: Laxague, Francisco, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hdjr8m5b9hbgjgn0peplcdaooo